Friday, 29 May 2015 21:08

Anticoagulation news items. Week commencing 25th May 2015

Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system

British Journal of Clinical Pharmacology

Reports of drug-induced liver injury associated with NOACs including acute liver failure events represented 3.7% (n = 146) and 1.7% (n = 222) of all reports for rivaroxaban and dabigatran, respectively. Disproportionality signals emerged for rivaroxaban in primary analysis.

 

Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures

JAMA Internal Medicine

This retrospective cohort study of patients whose warfarin therapy was interrupted for invasive diagnostic or surgical procedures (total 1812) found use of bridging increased the rate of clinically relevant bleeding (2.7% v 0.2% in those with no bridging); VTE rates were similar.

 

Standard vs Modified Antiplatelet Preparation for Preventing Thromboembolic Events in Patients With High On-Treatment Platelet Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm: A Randomized Clinical Trial

JAMA Neurology

This single-centre study reports that in patients undergoing coiling for unruptured aneurysms, use of a modified antiplatelet regimen for those with high on-treatment platelet reactivity reduced the rate of thromboembolic events vs. standard antiplatelet therapy.

 

Longer Versus Shorter Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis

Annals of Internal Medicine

This review of 9 RCTs reports that longer-duration dual antiplatelet therapy (DAPT) following drug-eluting stent placement reduced MI risk (RR 0.73, 95% CI 0.58-0.92) but increased mortality (1.19, 1.04-1.36) and major bleeding risk (1.63, 1.34-1.99]) vs. shorter-duration DAPT.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services